Rallybio Corporation and Avenzo Therapeutics conducted a merger call on June 1, 2026, to discuss their proposed combination.
The call opened with remarks from Steve Uden, co-founder, president, chief executive officer and director at Rallybio. He noted that the discussion would include forward-looking statements on the expected timing, completion and outcomes of the transaction, along with plans for the combined company such as clinical development and cash runway milestones.